Radiotherapy combined with chemoimmunotherapy improves survival compared to chemoimmunotherapy alone as first-line treatment for oligometastatic esophageal squamous cell carcinoma.

Strahlenther Onkol · 2025 · PMC12488787 · PMID 39805975

Europe PMC DOI

hedged sentences

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

on the threshold of significanceP = 0.052so close (0.05 < p ≤ 0.1)

7.3 months, P = 0.003) between the group receiving radiotherapy (RT) for all lesions, the group receiving RT for partial lesions, and the CIT group, while OS was on the threshold of significance (median OS: 29.4 vs. 17.3 vs. 13.4 months, P = 0.052).

also in 22 other papers

did not reach statistical significanceno p-value reported

This study found that adding RT for patients with 1–2 metastatic lesions can achieve superior PFS, although it did not reach statistical significance in OS, probably due to the small sample size.

also in 75,868 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.